Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis

Sun Kyoung Lee, Kwang Kyun Park, Hyun Jeong Kim, Junhee Park, Seung Hwa Son, Ki Rim Kim, WonYoon Chung

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Breast cancer mainly spreads to bone, causing decreased survival of patient. Human antigen R (HuR) and chemokines are important molecules associated with mRNA stability and cell-cell interaction in cancer biology. Here, HuR knockdown inhibited bone metastasis and osteolysis of metastatic breast cancer cells in mice and HuR expression promoted the metastatic ability of cancer cells via CCL20 and GM-CSF. In contrast with the findings for GM-CSF, ELAVL1 and CCL20 expressions were markedly increased in breast tumor tissues and ELAVL1 expression showed a strong positive correlation with CCL20 expression in breast cancer subtypes, particularly the basal-like subtype. Metastasis-free survival and overall survival were decreased in the breast cancer patients with high CCL20 expression. We further confirmed the role of CCL20 in breast cancer bone metastasis. Intraperitoneal administration of anti-CCL20 antibodies inhibited osteolytic breast cancer bone metastasis in mice. Treatment with CCL20 noticeably promoted cell invasion and the secretion of MMP-2/9 in the basal-like triple-negative breast cancer cell lines, not the luminal. Moreover, CCL20 elevated the receptor activator of nuclear factors kappa-B ligand/osteoprotegerin ratio in breast cancer and osteoblastic cells and mediated the crosstalk between these cells. Collectively, HuR-regulated CCL20 may be an attractive therapeutic target for breast cancer bone metastasis.

Original languageEnglish
Article number9610
JournalScientific reports
Volume7
Issue number1
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Bone Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Antigens
Granulocyte-Macrophage Colony-Stimulating Factor
Survival
Triple Negative Breast Neoplasms
RANK Ligand
Osteoprotegerin
Bone and Bones
Osteolysis
RNA Stability
Matrix Metalloproteinases
Chemokines
Cell Communication
Anti-Idiotypic Antibodies
Neoplasms
Cell Line

All Science Journal Classification (ASJC) codes

  • General

Cite this

Lee, Sun Kyoung ; Park, Kwang Kyun ; Kim, Hyun Jeong ; Park, Junhee ; Son, Seung Hwa ; Kim, Ki Rim ; Chung, WonYoon. / Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. In: Scientific reports. 2017 ; Vol. 7, No. 1.
@article{2d2491c82aeb4ba8aef206f036b52fc0,
title = "Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis",
abstract = "Breast cancer mainly spreads to bone, causing decreased survival of patient. Human antigen R (HuR) and chemokines are important molecules associated with mRNA stability and cell-cell interaction in cancer biology. Here, HuR knockdown inhibited bone metastasis and osteolysis of metastatic breast cancer cells in mice and HuR expression promoted the metastatic ability of cancer cells via CCL20 and GM-CSF. In contrast with the findings for GM-CSF, ELAVL1 and CCL20 expressions were markedly increased in breast tumor tissues and ELAVL1 expression showed a strong positive correlation with CCL20 expression in breast cancer subtypes, particularly the basal-like subtype. Metastasis-free survival and overall survival were decreased in the breast cancer patients with high CCL20 expression. We further confirmed the role of CCL20 in breast cancer bone metastasis. Intraperitoneal administration of anti-CCL20 antibodies inhibited osteolytic breast cancer bone metastasis in mice. Treatment with CCL20 noticeably promoted cell invasion and the secretion of MMP-2/9 in the basal-like triple-negative breast cancer cell lines, not the luminal. Moreover, CCL20 elevated the receptor activator of nuclear factors kappa-B ligand/osteoprotegerin ratio in breast cancer and osteoblastic cells and mediated the crosstalk between these cells. Collectively, HuR-regulated CCL20 may be an attractive therapeutic target for breast cancer bone metastasis.",
author = "Lee, {Sun Kyoung} and Park, {Kwang Kyun} and Kim, {Hyun Jeong} and Junhee Park and Son, {Seung Hwa} and Kim, {Ki Rim} and WonYoon Chung",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-09040-4",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. / Lee, Sun Kyoung; Park, Kwang Kyun; Kim, Hyun Jeong; Park, Junhee; Son, Seung Hwa; Kim, Ki Rim; Chung, WonYoon.

In: Scientific reports, Vol. 7, No. 1, 9610, 01.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis

AU - Lee, Sun Kyoung

AU - Park, Kwang Kyun

AU - Kim, Hyun Jeong

AU - Park, Junhee

AU - Son, Seung Hwa

AU - Kim, Ki Rim

AU - Chung, WonYoon

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Breast cancer mainly spreads to bone, causing decreased survival of patient. Human antigen R (HuR) and chemokines are important molecules associated with mRNA stability and cell-cell interaction in cancer biology. Here, HuR knockdown inhibited bone metastasis and osteolysis of metastatic breast cancer cells in mice and HuR expression promoted the metastatic ability of cancer cells via CCL20 and GM-CSF. In contrast with the findings for GM-CSF, ELAVL1 and CCL20 expressions were markedly increased in breast tumor tissues and ELAVL1 expression showed a strong positive correlation with CCL20 expression in breast cancer subtypes, particularly the basal-like subtype. Metastasis-free survival and overall survival were decreased in the breast cancer patients with high CCL20 expression. We further confirmed the role of CCL20 in breast cancer bone metastasis. Intraperitoneal administration of anti-CCL20 antibodies inhibited osteolytic breast cancer bone metastasis in mice. Treatment with CCL20 noticeably promoted cell invasion and the secretion of MMP-2/9 in the basal-like triple-negative breast cancer cell lines, not the luminal. Moreover, CCL20 elevated the receptor activator of nuclear factors kappa-B ligand/osteoprotegerin ratio in breast cancer and osteoblastic cells and mediated the crosstalk between these cells. Collectively, HuR-regulated CCL20 may be an attractive therapeutic target for breast cancer bone metastasis.

AB - Breast cancer mainly spreads to bone, causing decreased survival of patient. Human antigen R (HuR) and chemokines are important molecules associated with mRNA stability and cell-cell interaction in cancer biology. Here, HuR knockdown inhibited bone metastasis and osteolysis of metastatic breast cancer cells in mice and HuR expression promoted the metastatic ability of cancer cells via CCL20 and GM-CSF. In contrast with the findings for GM-CSF, ELAVL1 and CCL20 expressions were markedly increased in breast tumor tissues and ELAVL1 expression showed a strong positive correlation with CCL20 expression in breast cancer subtypes, particularly the basal-like subtype. Metastasis-free survival and overall survival were decreased in the breast cancer patients with high CCL20 expression. We further confirmed the role of CCL20 in breast cancer bone metastasis. Intraperitoneal administration of anti-CCL20 antibodies inhibited osteolytic breast cancer bone metastasis in mice. Treatment with CCL20 noticeably promoted cell invasion and the secretion of MMP-2/9 in the basal-like triple-negative breast cancer cell lines, not the luminal. Moreover, CCL20 elevated the receptor activator of nuclear factors kappa-B ligand/osteoprotegerin ratio in breast cancer and osteoblastic cells and mediated the crosstalk between these cells. Collectively, HuR-regulated CCL20 may be an attractive therapeutic target for breast cancer bone metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85028468180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028468180&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-09040-4

DO - 10.1038/s41598-017-09040-4

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 9610

ER -